Upstream Solutions for Cell and Gene Therapies
Polyplus is a leading upstream solutions provider for advanced biologic and cell and 유전자 치료제 production from research to commercial scale.
An innovator in nucleic acid delivery, the legacy portfolio features process-centric 핵산전달감염 reagents, kits, and support services for viral and non-viral delivery. Custom 플라스미드 vector design and 플라스미드 and protein manufacturing were integrated into the offer in 2022 to expand the products and services portfolio to help the industry optimize process economics while meeting strict scientific and regulatory standards.
Superior AAV titers in suspension cells Improves process economics Designed for Industrial scalability Available at GMP grade
Gold 표준 PEI-based 핵산전달감염 reagent for scalable virus production Highly Reproducible and reliable Available at GMP grade
Safe, efficient and secure Modulate LNP properties to adapt the mRNA biodistibution In vitro and in vivo proof of concept available
Ensure successful cloning through our innovative assembly technology, our powerful algorithm, our online design tool, and our dedicated 플라스미드 engine...
Unique scalable proprietary process allowing High purity 플라스미드 production very low 내독소 level in Research, HQ & GMP grades with tight timel...
Find more FAQs on cell & 유전자 치료제 here.
Our 핵산전달감염 reagents are manufactured in compliance with the ICH Q7 GMP part II guideline that ensure a validated and aseptic manufacturing process.
For lentivirus production, we recommend FectoVIR®-LV as it is currently the best product for this 어플리케이션, both in adherent and suspension cell culture systems.
PEIpro® and FectoVIR®-AAV are different both in terms of molecular structure and formulation. FectoVIR-AAV is especially well suited for AAV production in suspension cells.
Our unique and scalable proprietary process allows 플라스미드 production from 50mg to 20g in Research, HQ & GMP grades.
Within the LNP formulation, our Cationic lipids can modulate physicochemical properties and impact subsequent potency and biodistribution of formulated LNPs while improving mRNA stability.
Cell banking services, ATMP Manufacturing, and Fill & Finish.
This app note delves into the significance of fine-tuning process parameters for transient lentivirus production, includingplasmids, 핵산전달감염 reag...
Addressing large-scale manufacturing of clinical grade viral vectors using an optimized PEI-based 핵산전달감염 process.
Next-generation 핵산전달감염 reagent for large scale therapeutic lentiviral vector production.
Next-generation 핵산전달감염 reagent for large scale AAV manufacturing.
Overview of CAR-T cell generation using optimized 플라스미드 design and lentiviral vector production.
DNA and mRNA 핵산전달감염 both introduce genetic material into cells, differing in material and processes.
In recent years, 싸토리우스 has been continuously making acquisitions, expanding its portfolio by new, complementary technologies.
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.
Select your 핵산전달감염 reagent and benefit from our simplified shopping experience.